Review Article
Contralateral Risk-Reducing Mastectomy: Review of Risk Factors and Risk-Reducing Strategies
Table 2
Risk reduction of CBC associated with chemoprevention and surgery.
| | Risk reduction (95% CI) |
| Chemoprevention | | Antiendocrine | | Tamoxifen in BRCA1/2 mutation carriers | OR 0.5 (0.3–0.9) | Tamoxifen in noncarriers | 50% risk reduction | Aromatase inhibitors in noncarriers | 70% risk reduction | Chemotherapy | | Chemo versus no chemo | RR 0.6 (0.4–0.8) | Surgery | 20-year survival benefit | CRRM | | CRRM in BRCA1/2 mutation carriers | 14.9% | CRRM in nonmutation carriers | <1% |
|
|